Viking Global Investors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Viking Global Investors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,170,211	Closed	-$110M	–	113
2021 Q2	$110M	Sell	1,170,211 -945,446	-45%	-$87M	0.33%	63
2021 Q1	$195M	Sell	2,115,657 -1,547,219	-42%	-$131M	0.58%	51
2020 Q4	$268M	Buy	3,662,876 +2,489,132	+212%	+$185M	0.74%	45
2020 Q3	$91.2M	Sell	1,173,744 -297,675	-20%	-$20.5M	0.33%	64
2020 Q2	$81.8M	Sell	1,471,419 -519,851	-26%	-$22.2M	0.35%	55
2020 Q1	$59M	Buy	+1,991,270	New	+$67.4M	0.31%	51

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Viking Global Investors's HZNP Position: Q3 2021 in Review

Viking Global Investors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2021, closing a stake of 1,170,211 shares — an estimated $110M sold.

Viking Global Investors first reported a position in HZNP in Q1 2020 and held it in 6 quarters. The position peaked at $268M in Q4 2020. 572 funds tracked by Wall St. Rank hold HZNP as of Q3 2021.

Viking Global Investors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2021 after selling out during the quarter.
Viking Global Investors sold 1,170,211 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2021, an estimated $110M.
Viking Global Investors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2020 and held it in 6 quarters.
Viking Global Investors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $268M in Q4 2020.
572 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2021.

Based on Viking Global Investors's 13F filing for Q3 2021, filed 15 Nov 2021.